This large study has confirmed the previous impression that truncating mutations are associated with severe disease, but caution has to be exercised in using mutation type to predict disease course.
families with splice site mutations (15 from six), missense mutations (18 from six), and large deletions (18 from five) had an average age of onset of 27.8 years and at diagnosis of 33.4 years. Subjects with truncating mutations were significantly more likely to have symptoms before 20 years of age (p<0.001) and to develop at least two symptomatic CNS tumours in addition to vestibular schwannoma before 30 years (p<0.001). There were also significantly fewer multigenerational families with truncating mutations. Four further truncating mutations were in mosaic form and were associated with milder disease than other similar mutations.
This large study has confirmed the previous impression that truncating mutations are associated with severe disease, but caution has to be exercised in using mutation type to predict disease course.
(7Med Genet 1998;35:450-455) Keywords: neurofibromatosis type 2; somatic mosaicism; mutation; vestibular schwannoma Type 2 neurofibromatosis (NF2) is an autosomal dominantly inherited condition characterised by the development of bilateral vestibular schwannomas, schwannomas of other cranial, spinal, and cutaneous nerves, and cranial and spinal meningiomas.' 3 In 1987, the National Institutes of Health Consensus Meet- ing set out firm diagnostic criteria for NF2.'
These criteria meant that any person with bilateral vestibular schwannomas was assumed to have the disease and that 50% of offspring would be predicted to be affected. The NF2 gene was isolated in 19935 6 3 and some families on re-evaluation have been reclassified (for example, family 60). All subjects had undergone cranial imaging with MRI and the majority had undergone full spinal imaging. Any person with more than 10 tumours >0.5 cm on scan was considered severely affected. As previous classifications have been arrived at before the ability to detect tiny (1-2 mm) tumours, some modification is necessary if scan data are to be included. Current evidence would suggest that 75-90% of NF2 cases will have evidence of spinal tumours on MRI.8R l Many of these tumours will remain small and never become symptomatic. As a measure of severity, only tumours >0.5 cm have therefore been included. The great majority of patients have had some form of ophthalmological assessment. While this involved slit lamp examination, in most cases full assessment for retinal hamartomas and other features such as epiretinal membranes was sparse.
In addition to the 125 classical families, samples from 17 subjects fulfilling modified criteria for NF2 (table 1)2 and 87 subjects thought to be at risk of NF2, but not fulfilling criteria, were analysed as below.
MUTATION ANALYSIS
Genomic DNA samples prepared from peripheral blood were amplified with primers for all 17 exons of the NF2 gene, using primers previously described. 5 form, present in 10-38% of lymphocytes." One of these mutations (family 10) was transmitted in full form to an affected daughter, although the son who had inherited the high risk chromosome 22 had not inherited the mutation." Several of the mutations reported here have been previously published.". [17] [18] [19] [20] [21] However, 30/60 are reported here for the first time. The five large deletions are the subject of a further detailed report (Trueman et al, in preparation).
Six causative mutations (35%) have been identified in the 17 cases fulfilling modified criteria (two nonsense mutations, two frameshift deletions, one frameshift insertion, and one missense mutation). Four of 13 cases with unilateral VS + two other NF2 features had mutations, while 2/4 (50%) with multiple meningiomas + two other NF2 features were mutation positive. No mutations were found in samples from 87 other patients with features suggestive of NF2, but not fulfilling modified criteria. These varied from unilateral VS at a 68 (2) 25 (1) 23 .4, 25.5, and 28 years respectively. This is not fundamentally different from the nontruncating mutations, but significantly later than for frameshift and nonsense mutations.
Discussion
Since the first reports of germline mutations in NF2, there have been attempts to establish a link between the specific NF2 mutation and the disease phenotype.7 1 1 22 A general impression was that protein truncating mutations produced a more severe phenotype while certain splice site and missense mutations were associated with mild disease.7 18 19 22 Two recent papers have confirmed this impression on larger surveys of mutation proven subjects.8 9 However, clear statistical evidence for this has only been provided for data on age at onset, diagnosis, and hearing loss between nonsense and frameshifting mutations and splice site mutations.8 The present study confirms the age related differences between splice site and truncating mutations as well as providing statistical evidence for the first time for a milder disease course in families with missense mutations and large deletions. While some splice site mutations could lead to the production of a truncated protein by allowing read through of intronic sequence and introduction of a premature stop codon, and nonsense mutations could be ameliorated by skipping of the affected exon, we believe the subdivision is in general accurate. The weighted analysis allowing for intrafamilial correlation also provided significant results for presence and number of meningiomas, spinal tumours, and skin tumours in contrast to the previous report.8 Although 
